Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
This research output has an Altmetric Attention Score of 286. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2026.
All research outputs
#156,295
of 34,547,233 outputs
Outputs from Lancet Neurology
#106
of 4,649 outputs
Outputs of similar age
#2,328
of 381,416 outputs
Outputs of similar age from Lancet Neurology
#2
of 56 outputs
Altmetric has tracked 34,547,233 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,649 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 381,416 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.
